IDEAS home Printed from https://ideas.repec.org/a/adp/jctoij/v16y2020i3p45-48.html
   My bibliography  Save this article

Myocarditis in a 47-Year-Old Man with Myasthenia Gravis and Malignant Thymoma Following the Administration of a Tyrosine Kinase/CDK Inhibitor

Author

Listed:
  • Conor McDonald
  • Jonathan Wackett
  • Steve Philpot

    (Monash University, Melbourne, Australia
    Intensive Care Department, Cabrini Hospital, Melbourne, Australia)

  • Benjamin M Brady

    (Department of Hematology and Oncology, Cabrini Hospital, Melbourne, Australia
    Peter McCallum Cancer Centre, Melbourne, Australia)

Abstract

A 47-year-old man was admitted to an intensive care unit for increasing respiratory distress, persistent diarrhoea and general decline on a background of longstanding myasthenia gravis and metastatic thymic carcinoma. He had recently been involved in a phase 1 clinical trial with the drug FN-1501- an inhibitor of cyclin dependent kinases CDK2/CDK4/CDK6 and tyrosine kinase (TK) FLT3. The patient was found to have severe systolic dysfunction on echocardiography, consistent with myocarditis, for which he required inotropic support. It was only partially responsive to steroid treatment. In combination with the patient’s myasthenia gravis and deconditioning, the myocarditis contributed to the patient’s continued decline and ultimate death. This case explores the possibility that the patient’s myocardial injury and subsequent death was related to the trial drug FN-1501. An association between TK inhibitors and cardiotoxicity has been outlined in the past but the cardiac effects of CDK inhibitors is still in question. There is no data presently implicating FN-1501.

Suggested Citation

  • Conor McDonald & Jonathan Wackett & Steve Philpot & Benjamin M Brady, 2020. "Myocarditis in a 47-Year-Old Man with Myasthenia Gravis and Malignant Thymoma Following the Administration of a Tyrosine Kinase/CDK Inhibitor," Cancer Therapy & Oncology International Journal, Juniper Publishers Inc., vol. 16(3), pages 45-48, May.
    • Handle: RePEc:adp:jctoij:v:16:y:2020:i:3:p:45-48
    DOI: 10.19080/CTOIJ.2020.16.555937
    as

    Download full text from publisher

    File URL: https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555937.pdf
    Download Restriction: no
    File URL: https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555937.php
    Download Restriction: no
    File URL: https://libkey.io/10.19080/CTOIJ.2020.16.555937?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:jctoij:v:16:y:2020:i:3:p:45-48. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.